Treatment Protocol of Plozasiran in Adults With FCS

• Conditions: Familial Chylomicronemia

• Registration Number: NCT06796426
• Lead Sponsor: Arrowhead Pharmaceuticals

Brief Summary

This is a treatment program for the use of plozasiran in adults with Familial Chylomicronemia Syndrome (FCS). The program will enroll eligible patients ≥18 years of age, with fasting triglycerides ≥880 mg/dL (≥10 mmol/L) that is not adequately controlled with standard lipid-lowering therapy, and with a diagnosis of FCS. Patients will receive 25 mg of plozasiran by subcutaneous (sc) injection on Day 1 and every three months for a total of 5 injections. The duration of the program is 15 months.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-01
• Study First Submitted: 2025-01-22
• Study First Submitted QC: 2025-01-22
• Last Update Submitted: 2025-01-22
• Study First Posted: 2025-01-28
• Last Update Posted: 2025-01-28

Recruitment & Eligibility

• Status: AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Fasting triglycerides (TG) ≥ 880mg/dL that is not sufficiently controlled on standard lipid-lowering therapy
• Established diagnosis of FCS based on documented history of fasting TG levels in excess of 1000 mg/dL on repeated testing (for at least 3 prior occasions), and at least one of the following: a supportive genetic test, documented history of recurrent episodes of acute pancreatitis not caused by alcohol or cholelithiasis, documented history of recurrent hospitalizations for severe abdominal pain without other explainable cause, documented history of childhood pancreatitis, family history of hypertriglyceridemia-induced pancreatitis
• Willing to follow dietary counseling based on local standard of care, consistent with an intake of ≤ 20 g of fat per day
• If on medications for management of type 2 diabetes the dosing regimen must be stable.
• Participants of childbearing potential must agree to use a highly effective form of contraception in addition to a male condom during the program and for at least 90 days after the last dose of plozasiran

Exclusion Criteria

• Diabetes mellitus with any of the following at Day 1: newly diagnosed within the past 24 weeks, HbA1c ≥9.0% within the past 4 weeks, meaningful medical events relating to poor glycemic control, changes in basal insulin regimen of more than =/- 10 units within 12 weeks if insulin-dependent
• History of acute coronary syndrome events
• New York Heart Association Class III or IV heart failure or last known ejection fraction of <30%
• Clinical evidence of primary hypothyroidism, primary subclinical hypothyroidism, or secondary hypothyroidism
• History of stroke, transient ischemic attack, or peripheral artery disease within 24 weeks of first dose
• History of bleeding diathesis or coagulopathy
• Current diagnosis of nephrotic syndrome
• Eligible to receive any commercially available FDA-approved therapeutic for treatment of FCS unless proven to be ineffective or judged inappropriate by the treating physician

Note: Additional inclusion/exclusion criteria may apply per protocol

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (1)

Arrowhead Pharmaceuticals, Inc.; 🇺🇸 Pasadena, California, United States